OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
56
Results
Show all
Save search
Copy query
Show results for
Unknown
(56)
Publication Date
Release Date
2021
(15)
2022
(11)
2023
(10)
2017
(3)
2015
(3)
2025
(2)
2024
(2)
2016
(2)
2014
(2)
2011
(2)
2009
(2)
2020
(1)
2013
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
AusTraits, a curated plant trait database for the Australian flora.
Not available
S-EPMC8484355
|
biostudies-literature
Cite
Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years.
Not available
S-EPMC5299468
|
biostudies-literature
Cite
The FLUXNET2015 dataset and the ONEFlux processing pipeline for eddy covariance data.
Not available
S-EPMC7347557
|
biostudies-literature
Cite
A novel Alzheimer disease locus located near the gene encoding tau protein.
Not available
S-EPMC4573764
|
biostudies-literature
Cite
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Not available
S-EPMC4572072
|
biostudies-literature
Cite
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
Not available
S-EPMC5379914
|
biostudies-literature
Cite
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Not available
S-EPMC2846760
|
biostudies-literature
Cite
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Not available
S-EPMC3254252
|
biostudies-literature
Cite
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Not available
S-EPMC3163848
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets